16-[[(1S)-4-[[(1S)-4-[2-[2-[2-[[(5S)-5-aminohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-1-carboxy-4-oxobutyl]amino]-16-oxohexadecanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 16-[[(1S)-4-[[(1S)-4-[2-[2-[2-[[(5S)-5-aminohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-1-carboxy-4-oxobutyl]amino]-16-oxohexadecanoic acid
• 化学式: C₃₈H₆₉N₅O₁₂
• 分子量: 788.0
• InChiKey: JCGAAEZYAQEAOI-CHQNGUEUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  55
• 可旋转键数：
  38
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  273
• 氢给体数：
  8
• 氢受体数：
  13

文献信息

• DOUBLE-ACYLATED GLP-1 DERIVATIVES
  申请人：Novo Nordisk A/S

  公开号：EP2846823A1

  公开（公告）日：2015-03-18
• [EN] DOUBLE-ACYLATED GLP-1 DERIVATIVES<br/>[FR] DÉRIVÉS DU GLP-1 À DOUBLE ACYLATION
  申请人：NOVO NORDISK AS

  公开号：WO2013167454A1

  公开（公告）日：2013-11-14

  The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue and a second K residue, at positions corresponding to position 26, and 37, respectively, of GLP-1(7-37) (SEQ ID NO: 1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1: HOOC-(CH2)x-CO-*, and Chem. 2: HOOC-C6H4-O-(CH2)y-CO-*, in which x is an integer in the range of 8-16, and y is an integer in the range of 6-13; and the linker comprises Chem. 3: *-NH-(CH2)q-CH[(CH2)w-NR1R2]-CO-*, which is connected at its CO-* end to the epsilon amino group of the first or the second K residue of the GLP-1 analogue, and wherein q is an integer in the range of 0-5, R1 and R2 independently represent *-H or *-CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptide and linker intermediates. The derivatives are potent, stable, protracted, and suitable for oral administration.